Martin Shkreli (/ˈʃkrɛli/; born March 17, 1983) is an American investor and businessman. Shkreli is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, the co-founder and former CEO of pharmaceutical firms Retrophin and Turing Pharmaceuticals, and the former CEO of start-up software company Gödel Systems, which he founded in August 2016.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| TVTX | Travere Therapeutics, Inc. | 2026-03-03 12:09:33 | 28.64 | -0.89 | -3.01 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TVTX | 0001438533 | Travere Therapeutics, Inc. | US89422G1076 | — | 262383102 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | CA | 3611 VALLEY CENTRE DR | SAN DIEGO | CA | 92130 | UNITED STATES | US | 888-969-7879 | 3611 VALLEY CENTRE DR, SAN DIEGO, CA, 92130 | 3611 VALLEY CENTRE DR, SAN DIEGO, CA, 92130 | Retrophin, Inc. | — | 2011 | — | — | — | 1,309,524,306 | 90,922,868 | 92,241,550 | Martin Shkreli (/ˈʃkrɛli/; born March 17, 1983) is an American investor and businessman. Shkreli is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, the co-founder and former CEO of pharmaceutical firms Retrophin and Turing Pharmaceuticals, and the former CEO of start-up software company Gödel Systems, which he founded in August 2016. | 2026-02-26 17:11:31 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 1,309,524,306 | 685,383,824 | 109.8124 | 92,241,550 | 3,501,724 | 3.9461 |
| 2024 | 624,140,482 | -521,273,027 | -45.5096 | 88,739,826 | 12,641,341 | 16.6118 |
| 2023 | 1,145,413,509 | -393,357,757 | -25.5631 | 76,098,485 | 11,353,495 | 17.5357 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Peter Heerma | Chief Commercial Officer | 2024 | 503,750 | 0 | 299,155 | 353,500 | 14,697 | 1,513,360 |
| Jula Inrig | Chief Medical Officer | 2024 | 522,083 | 0 | 299,155 | 367,500 | 13,378 | 1,681,277 |
| Eric Dube | Chief Executive Officer, President, Director | 2024 | 822,000 | 0 | 1,607,400 | 865,200 | 14,697 | 5,204,877 |
| Christopher Cline | Chief Financial Officer | 2024 | 497,500 | 0 | 299,155 | 350,000 | 12,607 | 1,501,520 |
| Elizabeth Reed | Senior Vice President | 2023 | 468,417 | 0 | 648,327 | 230,300 | 14,917 | 2,018,708 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 497 |
| 2024 | 385 |
| 2023 | 380 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 490,728,000 | 233,175,000 | 145,238,000 |
| Cost Of Revenue | 10,339,000 | 7,744,000 | 11,450,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 206,011,000 | 217,496,000 | 244,990,000 |
| General And Administrative Expenses | 337,202,000 | 264,119,000 | 265,542,000 |
| Operating Expenses | 553,552,000 | 557,002,000 | 533,376,000 |
| Operating Income | -62,824,000 | -323,827,000 | -388,138,000 |
| Net Income | -25,546,000 | -321,545,000 | -111,399,000 |
| Earnings Per Share Basic | -0.29 | -4.08 | -1.5 |
| Earnings Per Share Diluted | -0.29 | -4.08 | -1.5 |
| Weighted Average Shares Outstanding Basic | 89,211,813 | 78,888,861 | 74,267,418 |
| Weighted Average Shares Outstanding Diluted | 89,211,813 | 78,888,861 | 74,267,418 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 93,035,000 | 58,535,000 | 58,176,000 |
| Marketable Securities Current | 145,384,000 | 73,325,000 | 248,638,000 |
| Accounts Receivable | 80,134,000 | 27,116,000 | 21,179,000 |
| Inventories | 36,155,000 | 6,200,000 | 9,410,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 437,565,000 | 416,702,000 | 616,775,000 |
| Marketable Securities Non Current | 84,377,000 | — | 260,037,000 |
| Property Plant And Equipment | 4,022,000 | 5,336,000 | 7,479,000 |
| Other Assets Non Current | 8,880,000 | 18,162,000 | 10,661,000 |
| Total Assets Non Current | 167,626,000 | 4,500,000 | 172,138,000 |
| Total Assets | 605,191,000 | 594,125,000 | 788,913,000 |
| Accounts Payable | 24,800,000 | 23,534,000 | 41,675,000 |
| Deferred Revenue | — | 2,815,000 | 7,096,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 3,194,000 | 14,291,000 | 5,237,000 |
| Total Liabilities Current | 159,904,000 | 200,751,000 | 177,908,000 |
| Long Term Debt | 311,724,000 | 310,310,000 | 377,263,000 |
| Other Liabilities Non Current | 7,601,000 | 6,796,000 | 8,485,000 |
| Total Liabilities Non Current | 330,459,000 | 334,297,000 | 410,195,000 |
| Total Liabilities | 490,363,000 | 535,048,000 | 588,103,000 |
| Common Stock | 9,000 | 9,000 | 7,000 |
| Retained Earnings | -1,472,713,000 | -1,447,167,000 | -1,125,622,000 |
| Accumulated Other Comprehensive Income | -1,189,000 | -80,000 | -1,456,000 |
| Total Shareholders Equity | 114,828,000 | 59,077,000 | 200,810,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 60,743,000 | 43,555,000 | 38,530,000 |
| Share Based Compensation Expense | 44,868,000 | 36,913,000 | 44,246,000 |
| Other Non Cash Income Expense | 1,457,000 | -7,944,000 | 3,626,000 |
| Change In Accounts Receivable | 27,822,000 | 6,001,000 | 11,264,000 |
| Change In Inventories | -5,016,000 | 3,771,000 | 39,420,000 |
| Change In Non Trade Receivables | -849,000 | 41,000 | 35,000 |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -85,000 | -17,563,000 | 24,763,000 |
| Change In Other Liabilities | -9,700,000 | 5,646,000 | -418,000 |
| Cash From Operating Activities | 37,784,000 | -237,475,000 | -280,021,000 |
| Purchases Of Marketable Securities | 237,142,000 | 125,757,000 | 443,942,000 |
| Sales Of Marketable Securities | 323,595,000 | 326,334,000 | 334,575,000 |
| Acquisition Of Property Plant And Equipment | — | — | 668,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | 404,000 | 40,000 | 0 |
| Cash From Investing Activities | 27,892,000 | 99,325,000 | 55,776,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 0 | 134,738,000 | 191,198,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -33,467,000 | 139,422,000 | 218,752,000 |
| Change In Cash | 34,500,000 | 359,000 | -3,512,000 |
| Cash At End Of Period | 93,035,000 | 58,535,000 | 58,176,000 |
| Income Taxes Paid | — | 453,000 | 578,000 |
| Interest Paid | 8,838,000 | 8,838,000 | 8,838,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -0.29 | -4.08 | -1.5 |
| Price To Earnings Ratio | -131.7586 | -4.2696 | -5.9933 |
| Earnings Growth Rate | -92.8922 | 172 | -65.6751 |
| Price Earnings To Growth Ratio | 1.4184 | -0.0248 | 0.0913 |
| Book Value Per Share | 1.2871 | 0.7489 | 2.7039 |
| Price To Book Ratio | 29.686 | 23.2619 | 3.3249 |
| Ebitda | 45,945,000 | -266,355,000 | -60,991,000 |
| Enterprise Value | 3,627,472,374.73 | 1,626,018,958.62 | 986,751,087.82 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 2.7147 | 5.2526 | 1.8787 |
| Capital Expenditures | 59,429,000 | 41,412,000 | 36,960,000 |
| Free Cash Flow | -21,645,000 | -278,887,000 | -316,981,000 |
| Return On Equity | -0.2225 | -5.4428 | -0.5547 |
| One Year Beta | 1.2647 | 1.2929 | 1.2364 |
| Three Year Beta | 1.2481 | 1.1011 | 1.0266 |
| Five Year Beta | 1.1124 | 0.9916 | 0.9908 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Dube Eric M | Director, CHIEF EXECUTIVE OFFICER | 2026-02-20 | 60,000 | A | 492,886 |
| Dube Eric M | Director, CHIEF EXECUTIVE OFFICER | 2026-02-20 | 60,000 | D | 432,886 |
| Dube Eric M | Director, CHIEF EXECUTIVE OFFICER | 2026-02-20 | 60,000 | D | 60,000 |
| REED ELIZABETH E | Chief Legal Officer and GC | 2026-02-17 | 10,000 | A | 115,211 |
| REED ELIZABETH E | Chief Legal Officer and GC | 2026-02-17 | 5,679 | D | 109,532 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Bell Investment Advisors, Inc | 2025-12-31 | 535 | 14 | 38.2143 |
| Invesco Ltd. | 2025-12-31 | 18,114,405 | 474,075 | 38.21 |
| NewEdge Advisors, LLC | 2025-12-31 | 246,875 | 6,461 | 38.21 |
| MACKENZIE FINANCIAL CORP | 2025-12-31 | 1,556,507 | 41,390 | 37.6059 |
| Ikarian Capital, LLC | 2025-12-31 | 1,398,486 | 36,600 | 38.21 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| TETON WESTWOOD FUNDS | 2025-12-31 | CLASS AAA | WESRX | 100,000 | 142,700 | 1.1311 |
| TETON WESTWOOD FUNDS | 2025-12-31 | CLASS C | WEICX | 100,000 | 142,700 | 1.1311 |
| TETON WESTWOOD FUNDS | 2025-12-31 | CLASS A | WEIAX | 100,000 | 142,700 | 1.1311 |
| Voya VARIABLE PORTFOLIOS INC | 2025-12-31 | Class S2 | IRCIX | 9,249 | 353,404.29 | 0.1071 |
| Voya VARIABLE PORTFOLIOS INC | 2025-12-31 | Class S | IRSSX | 9,249 | 353,404.29 | 0.1071 |